IL17RA and bullous pemphigoid: However, recently, a preclinical study demonstrated that blockade of IL-25 through anti-IL-17RA reduced off target organ infiltration with immune cells and improved antitumor activity, and a case series showed high IL-4 and IL-13 in skin lesions of ICI induced bullous pemphigoid, which responded to dupilumab treatment (91, 92).